Upcoming Stock Splits This Week (June 16 to June 20)
Confident Investing Starts Here:
Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
On the flip side, a reverse stock split shrinks the share count by combining existing shares, driving the price per share higher while keeping the total valuation intact. Companies often use this move to stay in compliance with stock exchange rules, particularly when their share price is hovering near delisting thresholds like Nasdaq's minimum requirement.
Whether to attract investor attention or to meet listing standards, these maneuvers can offer important clues about a company's current priorities and future strategy.
Let's take a look at the upcoming stock splits for the week.
Jianzhi Education Technology Group (JZ) – Beijing‑based Jianzhi is a digital education provider offering online learning platforms and professional development content to higher education institutions and individuals across China. On June 12, the company announced an upcoming 1‑for‑10 reverse ADS split to boost its ADS trading price and maintain Nasdaq listing compliance. The split is scheduled to be effective at the start of trading on June 16.
GlycoMimetics (GLYC) – U.S.-based GlycoMimetics is a clinical-stage biotech company developing treatments for sickle cell disease and cancer by targeting cell adhesion. On June 5, the company announced a 1-for-100 reverse stock split to support its planned merger with Crescent Biopharma. The split will take effect June 16, with shares trading under the new ticker CBIO as the combined company moves forward.
Neo-Concept International Group Holdings (NCI) – Neo-Concept is a Hong Kong-headquartered apparel supplier and importer serving global e-commerce platforms. Following shareholder approval at its May 9 meeting, the company is rolling out a 1-for-5 reverse share consolidation. The adjustment takes place June 16.
Shuttle Pharmaceuticals (SHPH) – Shuttle Pharmaceuticals is advancing a pipeline of radiation-sensitizing drugs aimed at improving cancer outcomes. On June 12, it unveiled a 1-for-25 reverse stock split to bring its share price back in line with Nasdaq's minimum bid requirement. The split becomes effective June 16, with SHPH shares trading on a split-adjusted basis that morning.
Jeffs' Brands (JFBR) – Jeffs' Brands operates data-driven e-commerce brands across major online marketplaces, including Amazon. After securing shareholder approval, the company announced on June 12 a 1-for-17 reverse stock split aimed at maintaining its Nasdaq listing. The change goes live June 16.
Security Matters (SMX) – Dublin-based Security Matters offers advanced digital tracking and authentication solutions for supply chains and product integrity. The company is implementing a 4.1-for-1 reverse stock split, which was approved earlier this spring and formally announced on June 12. The split is scheduled to take effect June 16.
Glucotrack (GCTK) – Glucotrack is a med-tech innovator developing non-invasive glucose monitoring solutions for diabetes management. To meet Nasdaq compliance standards, the company announced a 1-for-60 reverse stock split on June 12, following prior shareholder approval at its May 22 annual meeting. The split becomes effective June 16.
Regencell Bioscience Holdings (RGC) – Hong Kong–based Regencell is on a mission to treat neurocognitive disorders like ADHD and autism using traditional Chinese medicine. On June 2, the company unveiled a 38-for-1 forward stock split to boost liquidity and attract retail interest. Shareholders of record as of June 12 received their additional shares on June 13, and RGC began trading on a split-adjusted basis on June 16.
Sensei Biotherapeutics (SNSE) – Sensei is a clinical-stage biotech based in Boston, developing next-gen immunotherapies to take on cancer. On June 13, the company announced a 1-for-20 reverse stock split in an effort to meet Nasdaq's minimum price threshold and maintain its listing. The split takes effect on June 16, with adjusted trading kicking off on June 17.
RAPT Therapeutics (RAPT) – RAPT is advancing innovative therapies targeting inflammatory and autoimmune diseases. On June 13, the company rolled out a 1-for-8 reverse stock split aimed at reshaping its capital structure. The move becomes official on June 16, with split-adjusted shares starting to trade on June 17.
FibroGen (FGEN) – FibroGen is a biotech company focused on fibrosis and other serious diseases. On June 12, it announced a 1-for-25 reverse stock split designed to help the stock climb back above the Nasdaq's minimum bid requirement. The split becomes effective on June 16, with trading on a split-adjusted basis beginning June 17.
Interactive Brokers Group (IBKR) – A powerhouse in online trading, Interactive Brokers is known for serving active investors with low-cost, high-tech tools. On April 15, the company declared a 4-for-1 forward stock split to make shares more accessible to a broader investor base. Shareholders of record on June 16 received the extra shares on June 17, and IBKR stock began trading at the new price on June 18.
TipRanks Stock Splits Calendar.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
37 minutes ago
- Business Wire
LFMD Investors Have Opportunity to Join LifeMD, Inc. Fraud Investigation with the Schall Law Firm
LOS ANGELES--(BUSINESS WIRE)-- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of LifeMD, Inc. ('LifeMD' or 'the Company') (NASDAQ: LFMD) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. LifeMD announced its Q2 2025 financial results on August 5, 2025. The Company revealed higher customer acquisition costs had added pressure on the business, especially related to its RexMD telehealth platform. Analysts from KeyBanc Capital Markets indicated that the Company 'took its eye off the ball' in the quarter, leading to its share price to drop more than 44.8% on the next day. If you are a shareholder who suffered a loss, click here to participate. We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at or by email at bschall@ The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
Business Insider
an hour ago
- Business Insider
Beyond Meat Stock (BYND) Gets Binned Despite Rubbishing Bankruptcy Fears
Beyond Meat (BYND) stock wilted over 5% today despite the plant food maker dismissing concerns over the future of the business. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Via a post on social media site X, the company, which makes plant-based meat alternatives, said: 'Recent media stories suggesting that Beyond Meat filed for bankruptcy are unequivocally false. We have not filed nor are we planning to file for bankruptcy.' Chapter 11 Claims It came in response to an article by Daniel Kline, co-editor-in-chief of TheStreet, who argued in a story published on August 14 that given how Beyond Meat has reported 'falling sales and dwindling cash,' that it is 'headed to Chapter 11 bankruptcy.' In the story, Kline also said that Beyond Meat 'admitted it's in trouble by hiring corporate restructuring expert John Boken from consultancy AlixPartners as interim chief transformation officer.' The company 'does have time to fend off a Chapter 11 bankruptcy filing, but it also has limited, if any, prospects to meet its impending cash needs,' Kline said. The company recently served up a weak set of Q2 results, with net revenues of $75 million, marking a 19.6% decrease from the previous year. U.S. retail channel revenues dropped by 26.7%. See below: It said that it was implementing significant cost reduction strategies, including a reduction in force and operational efficiency improvements. It said Boken had been hired as interim Chief Transformation Officer to lead these initiatives. Healthy Hopes The company's share price has declined 97% in the past five years as its alternative meat products have failed to catch on with consumers and businesses. There had been a lot of hype around the company and its stock when it went public in 2019. But unfortunately, the early promise of plant-based meat alternatives never materialized. However, there is still hope. According to Grand View Research, the global plant-based meat market size was valued at $7.17 billion in 2023 and is projected to reach $24.77 billion by 2030. This is as more individuals become aware of the health risks associated with excessive consumption of red and processed meats. Is BYND a Good Stock to Buy Now? On TipRanks, BYND has a Moderate Sell consensus based on 2 Hold and 4 Sell ratings. Its highest price target is $4. BYND stock's consensus price is $2.50, implying a $5.12% downside.
Business Insider
an hour ago
- Business Insider
BABA vs. AMZN: Which ‘Mega-Cap' Cloud Stock Has More Upside, According to Wall Street Analysts?
Mega-cap stocks are those with a market capitalization of $200 billion or more. Most of these stocks are associated with large, well-established companies with strong track records. Due to their sheer size, mega-cap stocks are often considered safe bets during uncertain macroeconomic times. Using TipRanks' Stock Comparison Tool, we will compare Alibaba (BABA) and Amazon (AMZN) to see which mega-cap stock has more upside ahead, according to Wall Street analysts. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Alibaba (NYSE:BABA) Stock Alibaba is China's largest e-commerce and cloud-services company, running platforms such as Taobao, Tmall, and AliCloud. The stock has surged more than 45% this year, fueled by AI-driven cloud demand and strong momentum in instant delivery services. Recently, Alibaba has ramped up efforts in its core e-commerce business. Taobao expanded its one-hour delivery service to 50 cities, hitting over 40 million daily orders during peak campaigns. The company launched a ¥10 billion ($1.4 billion) subsidy plan to compete with and Meituan in the fast-delivery space. In addition, Alibaba merged its food delivery unit, and travel services, Fliggy, into Taobao and Tmall to strengthen its retail ecosystem. Looking ahead, the company is set to report its Q1 FY26 earnings soon. Wall Street expects Alibaba to report earnings of $2.16 per share for Q1, down 6% from the year-ago quarter. The decline could be due to the company's heavy investment in logistics and delivery. Meanwhile, analysts project Q1 revenues at $35.49 billion, up 6% year-over-year. Is Alibaba Stock a Good Buy Right Now? Mizuho's Top analyst, Wei Fang, maintained an Outperform rating but trimmed the price target from $160 to $149, citing concerns about rising competition and lower near-term profitability. According to him, rising competition in China's local commerce sector, especially in food delivery and instant retail, is beginning to hurt the company's bottom line. Overall, Wall Street has a Strong Buy consensus rating on Alibaba stock based on 13 Buys and one Hold. The average Alibaba price target of $150.09 implies about 23.78% upside potential from current levels. Amazon Stock (NASDAQ:AMZN) Amazon, the global e-commerce and cloud leader, delivered better-than-expected Q2 2025 earnings. The stock has surged about 5% so far this year, driven by strength in its cloud unit, Amazon Web Services (AWS). The company is making continuous efforts to boost spending on AI infrastructure to drive long-term growth. At the same time, Amazon is doubling down on its grocery business. It recently expanded its 'Amazon Fresh' store rollout in the U.S. and is testing faster same-day grocery delivery to strengthen its retail footprint. This move is designed to increase customer loyalty and complement its Prime ecosystem. What Is the Price Target for Amazon Stock? In response to Amazon's latest grocery push, Morgan Stanley analyst Brian Nowak highlighted that expanding the grocery selection on should help the company cut delivery costs while lowering the minimum basket size. He noted that this move is part of Amazon's broader effort to capture a larger share of the $1.5 trillion offline grocery market. Based on 44 Buys and one Hold recommendation, Amazon stock earns a Strong Buy consensus rating on TipRanks. The average AMZN stock price target of $265.22 implies 14.8% upside potential from current levels. Conclusion Wall Street remains bullish on both Alibaba and Amazon stocks. However, analysts see greater upside potential in Alibaba. The Chinese giant is betting big on instant commerce and subsidies to defend market share. Meanwhile, Amazon is expanding its grocery and AI bets to drive long-term growth. While its upside may be smaller than Alibaba's, Amazon's stable growth and strong cash flow continue to earn Wall Street's confidence.
